Business
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026 Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission expected in H2 2026 Approximately $85.6 million in cash and cash equivalents on hand, supporting execution across planned 2026 milestones Received gross proceeds of $23.0 million from exercises of Tranche A warrants from August 2025 financing, with cash runway into early 2027 BURLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) --
About this update from Fractyl Health, Inc.
[{"type":"image","alt":"Fractyl Health, Inc.","displaySize":"","headline":null,"caption":"Fractyl Health, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":104,"url":"https://media.zenfs.com/en/globenewswire.com/9ee0df9b33cb03fd3cc1257160c381e5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/grE4KlKD7t64vNihlXguCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9ee0df9b33cb03fd3cc1257160c381e5","width":300,"height":104}},"lazy":false},{"type":"text","content":"Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026","length":87,"tagName":"p"},{"type":"text","content":"Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission expected in H2 2026","length":102,"tagName":"p"},{"type":"text","content":"Approximately $85.6 million in cash and cash equivalents on hand, supporting execution across planned 2026 milestones ","length":117,"tagName":"p"},{"type":"text","content":"Received gross proceeds of $23.0 million from exercises of Tranche A warrants from August 2025 financing, with cash runway into early 2027","length":138,"tagName":"p"},{"type":"text","content":"BURLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today outlined its strategic outlook for 2026, highlighting anticipated clinical and regulatory milestones across its Revita® and Rejuva® programs.","length":395,"tagName":"p"},{"type":"text","content":"“As we enter 2026, we believe Fractyl is positioned for a definitional year, and our focus is on disciplined execution with an accelerating cadence of clinical and regulatory milestones and progress,” said Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health. “We are rapidly advancing Revita as an outpatient endoscopic therapy designed to address a root cause of obesity. This year, we expect to deliver pivotal data and potential PMA filing in what we see as the single biggest problem in obesity today: post-GLP-1 weight maintenance. With millions of patients expected to start and then stop taking a GLP-1 this year, we believe weight loss maintenance is the new unmet need in ...